05/17/22 4:30 PMNasdaq : RGLS conferencesRegulus Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer ofRHEA-AIneutral
05/12/22 4:05 PMNasdaq : RGLS earningsRegulus Therapeutics Reports First Quarter 2022 Financial Results and Recent UpdatesRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical companyRHEA-AIpositive
05/11/22 8:00 AMNasdaq : RGLS Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" orRHEA-AIneutral
05/05/22 4:05 PMNasdaq : RGLS earningsRegulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference CallRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report its first quarter 2022 financialRHEA-AIneutral
03/24/22 8:00 AMNasdaq : RGLS clinical trialRegulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's HospitalRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), todayRHEA-AIneutral
03/10/22 4:05 PMNasdaq : RGLS earningsRegulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent UpdatesRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced its financial results for the fourth quarter and yearRHEA-AIneutral
03/03/22 5:15 PMNasdaq : RGLS earningsRegulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference CallRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has scheduled its fourth quarter and year-endRHEA-AIneutral
02/24/22 8:00 AMNasdaq : RGLS clinical trialRegulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport SyndromeRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the completion of enrollment in the Phase 2 HERA clinicalRHEA-AIpositive
02/10/22 4:30 PMNasdaq : RGLS conferencesRegulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer ofRHEA-AIneutral
01/20/22 5:18 PMNasdaq : RGLS Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company has completed a pre-investigational newRHEA-AIpositive